title: Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity.
abstract: A series of 2,5-bis-substituted 3,6-diaziridinyl-1,4-benzoquinones have been tested for their ability to be reduced by the two-electron NAD(P)H:(quinone acceptor) oxidoreductase [DT-diaphorase (DTD); EC 1.6.99.2]. Symmetrically alkyl-substituted carbamoyl ester analogs of 2,5-ethyl(carboethoxyamino)3,6-diaziridinyl-1,4- benzoquinone [AZQ], 3,6-diaziridinyl-1,4-benzoquinone (DZQ), and its 2,5-dimethyl derivative (MeDZQ) were tested. The rate of reduction by DTD was DZQ greater than MeDZQ greater than n-butyl- (D5) greater than sec-butyl- (D7) greater than n-propyl- (D3) greater than methyl- (D1) greater than ethyl- (AZQ) greater than i-butyl- (D6) greater than i-propyl- (D4) substituted derivatives. The hydroxyethylamino analog (BZQ) was not a substrate for DTD. The order of toxicity to HT-29 human colon carcinoma cells (at 1-log cell kill) was MeDZQ greater than DZQ greater than BZQ greater than D1 greater than D5 greater than AZQ greater than D7 greater than D3 greater than D6 greater than D4. Dicumarol, a known inhibitor of DTD, was capable of inhibiting the cytotoxicity of DZQ, MeDZQ, AZQ, D3, D4, D5, D6, and D7, with little inhibition of D1 cytotoxicity. Alkaline elution assays suggested that DZQ induced DNA strand breaks, whereas MeDZQ induced DNA interstrand crosslinks in HT-29 cells. The formation of both classes of lesions was inhibited by dicumarol. DZQ and MeDZQ were 5-6-fold less cytotoxic to the DTD-deficient BE cell line, whereas BZQ was more cytotoxic to this cell line than the HT-29 cell line. BZQ was capable of inducing dicumarol-insensitive DNA interstrand crosslinks in both cell lines. In summary, these data show a trend between the rate of reduction by DTD of an analog and its ability to induce cytotoxicity in HT-29 cells, and they support a role for DTD in the bioreductive activation of AZQ and its analogs.
authors.affiliation: School of Pharmacy and Comprehensive Cancer Center, University of Southern California, Los Angeles 90033.
authors.forename: N W
authors.initials: NW
authors.lastname: Gibson
authors.forename: J A
authors.initials: JA
authors.lastname: Hartley
authors.forename: J
authors.initials: J
authors.lastname: Butler
authors.forename: D
authors.initials: D
authors.lastname: Siegel
authors.forename: D
authors.initials: D
authors.lastname: Ross
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000633:toxicity; D001388:Aziridines / Q000378:metabolism* / Q000633:toxicity; D016227:Benzoquinones / Q000378:metabolism* / Q000633:toxicity; D003110:Colonic Neoplasms / Q000188:drug therapy; D004249:DNA Damage; D006801:Humans; D008099:Liver / Q000201:enzymology; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000378:metabolism* / Q000494:pharmacology; D010084:Oxidation-Reduction; D051381:Rats; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D001388:Aziridines; D016227:Benzoquinones; C073715:2,5-dimethyl-3,6-diaziridinyl-1,4-benzoquinone; C009970:ethylenimine quinone; C045315:NSC 224070; D016660:NAD(P)H Dehydrogenase (Quinone); C029108:diaziquone